Systemic immune profiling of Omicron-infected subjects inoculated with different doses of inactivated virus vaccine-Reference-Cited by-同舟云学术

Systemic immune profiling of Omicron-infected subjects inoculated with different doses of inactivated virus vaccine

Published:2023-10 Issue:21 Volume:186 Page:4615-4631.e16
ISSN:0092-8674
Container-title:Cell
language:en
Short-container-title:Cell

Author:

Yu Shanhe,Lin Yingni,Li Yong,Chen Shijun,Zhou Lina,Song Hejie,Yang Cuiping,Zhang Haiqing,Zhou Jianping,Sun Shunchang,Li Yanan,Chen Juan,Feng Ruixue,Qiao Niu,Xie Yinyin,Zhang Ruihong,Yin Tong,Chen Saijuan,Li Qingyun,Zhu Jiang,Qu Jieming^ORCID

Publisher

Elsevier BV

Subject

General Biochemistry, Genetics and Molecular Biology

Reference80 articles.

1. Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa;Viana;Nature,2022

2. Neutralizing immunity in vaccine breakthrough infections from the SARS-CoV-2 Omicron and Delta variants;Servellita;Cell,2022

3. Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution;Cao;Nature,2023

4. Infectiousness of SARS-CoV-2 breakthrough infections and reinfections during the Omicron wave;Tan;Nat. Med.,2023

5. Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study;McMenamin;Lancet Infect. Dis.,2022

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Systemic and dynamic immune landscape of Omicron-infected subjects treated with Lianhua Qingwen capsules;Acta Pharmaceutica Sinica B;2024-09

2. T cell hybrid immunity against SARS-CoV-2 in children: a longitudinal study;eBioMedicine;2024-07

3. Three in one: An effective and universal vaccine expressing heterologous tandem RBD trimer by rabies virus vector protects mice against SARS-CoV-2;Antiviral Research;2024-07

4. Harnessing T-Cells for Enhanced Vaccine Development against Viral Infections;Vaccines;2024-04-29

5. Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment with LCAR-B38M CAR T cells: 5-year follow-up of the LEGEND-2 trial;Journal of Hematology & Oncology;2024-04-24